The Memorial Sloan Kettering Cancer Center is conducting Phase I clinical study (NCT06017258) that tests CAR T cell therapy using a combination of acute myelogenous leukemia (AML) marker and an IL-18-armored construct (CD371-YSNVZIL-18). Here, IL18 is linked to acute myeloid leukemia.